NCT03520920View on ClinicalTrials.gov

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 4, 2018

Primary Completion Date

August 28, 2020

Study Completion Date

August 28, 2020

Conditions
Marginal Zone LymphomaFollicular LymphomaDiffuse Large B-Cell Lymphoma
Interventions
DRUG

Zanubrutinib

Administered zanubrutinib 160 mg orally (PO) BID continuously

DRUG

Rituximab

Administered rituximab 375 mg/m\^2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.

Trial Locations (4)

150000

Harbin Medical University Cancer Hospital, Harbin

200092

Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

221000

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

430030

Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT03520920 - BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) | Biotech Hunter | Biotech Hunter